Recent data have demonstrated that SGLT2 inhibitors can attenuate chronic inflammation and hepatic steatosis and protect tissues against oxidative damage not only by their glucose-lowering effects but also via either lowering free-radical generation or by boosting the biological antioxidative system [49–54]. The gene discussed is SLC5A2; the disease is Hepatic steatosis.